Jinarc® is a prescription drug registered to Hong Kong Department of Health. Professional advice from doctors should be strictly followed when taking these drugs. For enquiry, please consult your doctor or pharmacist.

Jinarc® has been proven effective in clinical studies to:

Jinarc® is a prescription drug registered to Hong Kong Department of Health. Professional advice from doctors should be strictly followed when taking these drugs. For enquiry, please consult your doctor or pharmacist.

If you are prescribed Jinarc®, you can refer to the below dosing information:

A: Jinarc® may cause adverse reactions related to water loss such as thirst, polyuria, nocturia, and pollakiuria. Hence, patients have to be instructed to drink water or other aqueous fluids at the first sign of thirst in order to avoid excessive thirst or dehydration. Additionally, patients have to drink 1-2 glasses of fluid before bedtime regardless of perceived thirst and replenish fluids overnight with each episode of nocturia.

A: Most importantly, you must not drink grapefruit juice during the course of Jinarc® treatment. On the other hand, there is limited clinical data on the impact of alcohol and smoking on the efficacy and safety of Jinarc®. Nevertheless, we recommend to adopt a healthy lifestyle which is good to your conditions.

A: Please consult a doctor before taking other medications. From clinical data, Jinarc® has been known or suspected for interactions with drugs categorized as moderate or strong CYP3A inhibitors.

*Examples of moderate CYP3A inhibitors include amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil; examples of strong CYP3A inhibitors include itraconazole, ketoconazole, ritonavir, clarithromycin.

A: Jinarc® is generally well tolerated: thirst, polyuria, nocturia, and pollakiuria may occur. Jinarc® has minor influence on the ability to drive or use machines. However, when driving vehicles or using machines it has to be taken into account that occasionally dizziness, asthenia or fatigue may occur.

A: People who have had an allergic reaction to the active substance tolvaptan, any of the excipients of Jinarc® , benzazepine or benzazepine derivatives should not take it. Also, patients with anuria, volume depletion, hypernatraemia, patients who cannot perceive or respond to thirst, and patients who are pregnant or breast-feeding should not take it. Moreover, patients with elevated liver enzymes and/or signs or symptoms of liver injury prior to initiation of treatment that meet the requirements for permanent discontinuation of Jinarc® should not take it as well. For enquiry, please consult your doctor or pharmacist.

A: Jinarc® may cause adverse reactions related to water loss such as thirst, polyuria, nocturia, and pollakiuria. Hence, patients have to be instructed to drink water or other aqueous fluids at the first sign of thirst in order to avoid excessive thirst or dehydration. Additionally, patients have to drink 1-2 glasses of fluid before bedtime regardless of perceived thirst and replenish fluids overnight with each episode of nocturia.

A: Most importantly, you must not drink grapefruit juice during the course of Jinarc® treatment.
On the other hand, there is limited clinical data on the impact of alcohol and smoking on the efficacy and safety of Jinarc®. Nevertheless, we recommend to adopt a healthy lifestyle which is good to your conditions.

A: Please consult a doctor before taking other medications. From clinical data, Jinarc® has been known or suspected for interactions with drugs categorized as moderate or strong CYP3A inhibitors.

*Examples of moderate CYP3A inhibitors include amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil; examples of strong CYP3A inhibitors include itraconazole, ketoconazole, ritonavir, clarithromycin.

A: Jinarc® is generally well tolerated: thirst, polyuria, nocturia, and pollakiuria may occur. Jinarc® has minor influence on the ability to drive or use machines. However, when driving vehicles or using machines it has to be taken into account that occasionally dizziness, asthenia or fatigue may occur.

A: People who have had an allergic reaction to the active substance tolvaptan, any of the excipients of Jinarc® , benzazepine or benzazepine derivatives should not take it. Also, patients with anuria, volume depletion, hypernatraemia, patients who cannot perceive or respond to thirst, and patients who are pregnant or breast-feeding should not take it. Moreover, patients with elevated liver enzymes and/or signs or symptoms of liver injury prior to initiation of treatment that meet the requirements for permanent discontinuation of Jinarc® should not take it as well. For enquiry, please consult your doctor or pharmacist.

References :
1. Jinarc Hong Kong prescribing information. May 2020.
2. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18.
3. Jinarc Patient Education Brochure. Aug 2020.
4. PKD Charity: Diet and Lifestyle. Available at: https://www.pkdcharity.org.uk/about-adpkd/living-with-adpkd/diet-and-lifestyle. Accessed: 20 Apr 2021.

Jinarc® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. of Japan.

The information on this webpage only includes general information, which is only for the personal reference of those who visit this website, and does not replace the professional advice and instructions given to patients by doctors or pharmacists. For details, please consult your doctor or pharmacist. You should not rely solely on the content contained in this webpage, and we assume no responsibility or consequences for any omissions or errors in the content. Otsuka Pharmaceutical (H.K.) Limited does not endorse or recommend any products disclosed or displayed on this website, and does not make any representations or guarantees regarding any information contained. The information on this website is only applicable to people who visit this website in Hong Kong, and the information contained about the drug may be different from the drug labels of other countries.

Medical professionals should refer to the detailed prescribing information of the product registered with the Pharmacy and Poisons Board of Hong Kong for complete product information. The information published on this website is not a substitute for your medical judgment. We kindly ask medical staff to evaluate the information provided on this website with professional judgment before making any evaluation or treatment decisions. Under any circumstances, Otsuka Pharmaceutical (H.K.) Limited shall not be liable for any damage, loss or injury caused by using or relying on the information provided on this website in any form.

HKOP-JIN-202109-001

Copyright ©️ Otsuka Pharmaceutical (HK) Limited. Powered by BioSpark Ltd.

Contact us

We are glad to help you understand more about our products. If you have any questions regarding our products, please contact us by phone.

Otsuka Pharmaceutical (H.K.) Ltd.
Address: 21/F, East Exchange Tower, 38 Leighton Road, Causeway Bay, Hong Kong.
Tel: (852) 2881 6299

Terms & Conditions

Welcome to the website of Otsuka Pharmaceutical (H.K.) Ltd. We request for your time to read and understand the Terms of Use as below. Your acceptance of these Terms is indicated by browsing and using this website. Otsuka Pharmaceutical (H.K.) Ltd reserves the right to revise the Terms of Use as necessary. All information, trademarks and other intellectual properties from this website are assets of Otsuka Pharmaceutical (H.K.) Ltd and its related enterprises, and are protected by Copyright. While permissible for duplication for personal use, unauthorized modifications, copying, leasing and lending, transfer and broadcasting are strictly prohibited. Any information form this website is prohibited for sale, resale or other commercial purposes.

Otsuka Pharmaceutical (H.K.) Ltd can redirect your visit to outside of its website via hyperlinks. Otsuka Pharmaceutical (H.K.) Ltd shall not be liable to any issues pertaining to the information, accuracy and functionality of those websites. Otsuka Pharmaceutical (H.K.) Ltd is not responsible for any changes made to the hyperlinked websites although such links are provided solely based on goodwill.

Otsuka Pharmaceutical (H.K.) Ltd shall take ownership of all feedback, posts, articles, drawings, ideas and other information submitted to this website. There shall be no restrictions on how Otsuka Pharmaceutical (H.K.) Ltd utilizes such information.

Cookies Policy

In this Cookies Policy, “Otsuka” refers to the Otsuka Pharmaceutical (H.K.) Ltd.

Otsuka does not use and collect cookies when you visit our site. Otsuka also adopts applicable means to prevent any third party from unauthorized or accidental access, processing, erasure, loss or use of cookies that may contain personal data.

Last updated August 2021

©️ Otsuka Pharmaceutical (H.K.) Ltd.

使用條款

 

在本使用條款中,「香港大塚製藥」指Otsuka Pharmaceutical (H.K.) Ltd.。

歡迎使用香港大塚製藥網站。請於使用本網站前認真閱讀此使用條款。在瀏覽或使用本網站時,即表示同意受本條款約束。香港大塚製藥保留隨時修訂此條款的權利。

本網站所有的資料、商標或其他智慧財產權皆屬於香港大塚製藥或其相關企業的財產,並受著作權法保護。基於個人用途而進行複製是允許的,但禁止未經授權的修改、抄襲、出租、外借、傳輸與播送。本網站的資料不得出售或作任何圖利用途。

香港大塚製藥網站的連結可以帶您到香港大塚製藥網站以外的網路世界,香港大塚製藥對於這些網站的內容、正確性或功能並不承擔任何責任。本公司乃是基於善意提供這些網站的連結,但是我們無法對所連結之網站的任何變動負任何責任。

而於本網站參加任何類型的活動,當中任何遞交的意見、發表、文章、繪圖、概念或其他資料等,香港大塚製藥將持有其擁有權,而使用的方式將不被限制。

Cookie 政策

在本Cookie政策中,「香港大塚製藥」指Otsuka Pharmaceutical (H.K.) Ltd.。

當您訪問我們的網站時,香港大塚製藥不會使用和收集 cookie。 香港大塚製藥還會採取適當的方法來防止任何第三方未獲准許或意外地查閱、處理、刪除、喪失或使用可能包含個人數據的 cookie。

最後更新於:2021 年 8 月

©️ Otsuka Pharmaceutical (H.K.) Ltd.